Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound Shuangdi
- Development stage
- Unknown
- Lead developer
- Fudan University Shanghai Cancer Center
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Compound Shuangdi is a Traditional Chinese Medicine (TCM) compound formulation developed by the Fudan University Shanghai Cancer Center, specifically for the treatment of intrahepatic cholangiocarcinoma (ICC). The formula is characterized by its primary components, *Rehmannia glutinosa* (Sheng Di Huang) and *Lycium chinense* (Di Gu Pi), which are combined with other herbal ingredients to target tumor progression. Mechanistically, Compound Shuangdi has been shown to inhibit the epithelial-mesenchymal transition (EMT) and modulate the tumor microenvironment, primarily through the suppression of the TGF-β/Smad signaling pathway. It is typically used as an integrative therapy alongside standard chemotherapy (such as gemcitabine and cisplatin) to enhance therapeutic efficacy, reduce metastasis, and improve the quality of life for patients with advanced biliary tract cancers.
- Brand names
- Compound Shuangdi Granule
- Other names
- Compound Shuangdi FormulaShuangdi Formula复方双地
02
Targets
TGFB (GARP–latent transforming growth factor beta 1 complex)
Beyond the preview
Go deeper on Compound Shuangdi.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Compound Shuangdi.